Bellicum Pharmaceuticals, Inc.
BLCM
BLCM was delisted on the 1st of June, 2023.
78 hedge funds and large institutions have $149M invested in Bellicum Pharmaceuticals, Inc. in 2016 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 29 increasing their positions, 23 reducing their positions, and 16 closing their positions.
26% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 23
4% less funds holding
Funds holding: 81 → 78 (-3)
19% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 16
55% less capital invested
Capital invested by funds: $333M → $149M (-$184M)
73% less call options, than puts
Call options by funds: $204K | Put options by funds: $753K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$6.72M |
| 2 |
First Eagle Investment Management
New York
|
+$3.11M |
| 3 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
+$2.24M |
| 4 |
QF
QVT Financial
New York
|
+$1.82M |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
+$839K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$8.54M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.2M |
| 3 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
-$5.37M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$4.69M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.37M |
BLCM Hedge Fund Activity: Q1 2016 in Review
78 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Bellicum Pharmaceuticals, Inc. (BLCM) for Q1 2016, worth a combined $149M — down 55% from $333M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of BLCM and 13 opened new positions — a net loss of 3 holders — while 23 trimmed existing stakes and 29 added.
The largest buyer was JP Morgan Chase, adding an estimated $6.72M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $8.54M sold.
- 78 institutional investors held Bellicum Pharmaceuticals, Inc. (BLCM) as of Q1 2016, down from 81 in Q4 2015.
- Funds reported $149M of Bellicum Pharmaceuticals, Inc. stock for Q1 2016, down 55% quarter-over-quarter.
- 13 funds opened new Bellicum Pharmaceuticals, Inc. positions in Q1 2016 and 16 closed out, a net change of -3 holders.
- The largest Bellicum Pharmaceuticals, Inc. buyer in Q1 2016 was JP Morgan Chase, an estimated $6.72M added.
- The largest Bellicum Pharmaceuticals, Inc. seller in Q1 2016 was Perceptive Advisors, an estimated $8.54M sold.
Based on aggregated 13F filings for Q1 2016.